Abstract:Introduction: Immune escape frequently occurs and restricts the durability of the antitumor immune response to radiotherapy. Programmed death 1 (PD-1) and programmed death ligand 1 (PD-L1) are important immune checkpoint molecules that could cause tumor cells to escape the host immune response. The aim of the study was to explore the role of PD-L1 in radioresistance and the antitumor effect of combined radiotherapy and anti-PD-L1 therapy in NSCLC.Methods: The role of the phosphoinositide 3-kinase/protein kinase B signal transducer and activator of transcription 3, epithelial-mesenchymal transition, and tripartite motif containing 21 in regulating PD-L1 expression after radiotherapy was investigated by small interfering-PD-L1 RNA transfection, immunohistochemistry, Western blot, and immunoprecipitation. The synergistic effect of radiotherapy and anti-PD-L1 antibody was evaluated in a mouse model. PD-L1 expression on tumor specimens was examined in a retrospective cohort of patients who received concurrent chemoradiotherapy.Results: PD-L1 expression was increased in vivo and in vitro after conventionally fractionated radiation. Radiotherapy in combination with anti-PD-L1 antibody synergistically enhanced antitumor immunity by promoting CD8-positive T cell infiltration and reducing the accumulation of myeloid derived suppressor cells and tumor-infiltrating regulatory T cells in a mouse model. Radiotherapy may up-regulate PD-L1 expression through the phosphoinositide 3-kinase/AKT and signal transducer and activator of transcription 3 pathways. PD-L1 may also stimulate cell migration and facilitate the epithelial-mesenchymal transition process to induce radioresistance. Moreover, down-regulating PD-L1 could alleviate radioresistance' by promoting apoptosis. Intriguingly, patients with negative PD-L1 expression had a significantly higher objective response rate (88% versus 43.1% [p < 0.001]) and disease control rate (100% versus 86.2% [p = 0.026]) than those with positive PD-L1 expression after delivery of radiotherapy.Conclusions: Conventionally fractionated radiotherapy in combination with anti-PD-L1 antibody shows a synergistic antitumor immunity in NSCLC. Furthermore, PD-L1 expression may be a significant clinical predictive factor for treatment response to radiotherapy in NSCLC. (C) 2017 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

PPDPF Promotes the Progression and Acts As an Antiapoptotic Protein in Non-Small Cell Lung Cancer.

PPDPF promotes lung adenocarcinoma progression via inhibiting apoptosis and NK cell-mediated cytotoxicity through STAT3

Targeting TFAP2C/PDCD6 Pathway by lncRNA PP7080 Expedites Tumorigenesis and Contributes to an Immunosuppressive Tumor Microenvironment in Non‐Small Cell Lung Cancer

Combined Radiotherapy and Anti–PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non–Small Cell Lung Cancer

PP4R1 accelerates the malignant progression of NSCLC via up-regulating HSPA6 expression and HSPA6-mediated ER stress

CDK16 Phosphorylates and Degrades P53 to Promote Radioresistance and Predicts Prognosis in Lung Cancer.

PP4R1 Induced Cancer Stemness by Upregulating the Expression of OCT4 Via the MAPK/ERK Pathway in NSCLC

Long Non-Coding RNA PANDAR Promoted Radiation and Cisplatin-Induced DNA Damage Repair Through ATR/CHK1 in NSCLC

PEDF Inhibits Non‑small Cell Lung Cancer Proliferation by Suppressing Autophagy Through Downregulation of AMPK‑ULK1 Signaling.

Elevated Expression of Podoplanin and Its Clinicopathological, Prognostic, and Therapeutic Values in Squamous Non-Small Cell Lung Cancer

Inhibition of protein phosphatase 5 suppresses non-small cell lung cancer through AMP-activated kinase activation

PPM1D Silencing by RNA Interference Inhibits the Proliferation of Lung Cancer Cells

PRC1 Promotes Cell Proliferation and Cell Cycle Progression by Regulating P21/p27-Prb Family Molecules and FAK-paxillin Pathway in Non-Small Cell Lung Cancer.

Knockdown Of Protein Phosphatase 4 Regulatory Subunit 1 Inhibits Growth Of Lung Cancer Cells In Vitro

PEST-containing nuclear protein regulates cell proliferation, migration, and invasion in lung adenocarcinoma

Synergistic Effect of PAF Inhibition and X-ray Irradiation in Non-Small Cell Lung Cancer Cells

LRPPRC Contributes to the Cisplatin Resistance of Lung Cancer Cells by Regulating MDR1 Expression

Programmed death ligand 1/programmed death 1 immune checkpoint regulate radioresistance non-small-cell lung carcinoma escape from natural killer cell immunotherapy

PFKL Promotes Cell Viability and Glycolysis and Inhibits Cisplatin Chemosensitivity of Laryngeal Squamous Cell Carcinoma

Protein tyrosine phosphatase PTPRO represses lung adenocarcinoma progression by inducing mitochondria-dependent apoptosis and restraining tumor metastasis

The PDRG1 is an Oncogene in Lung Cancer Cells, Promoting Radioresistance Via the ATM-P53 Signaling Pathway